These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 7532229)
1. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. Israeli RS; Miller WH; Su SL; Samadi DS; Powell CT; Heston WD; Wise GJ; Fair WR J Urol; 1995 Mar; 153(3 Pt 1):573-7. PubMed ID: 7532229 [TBL] [Abstract][Full Text] [Related]
2. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Israeli RS; Miller WH; Su SL; Powell CT; Fair WR; Samadi DS; Huryk RF; DeBlasio A; Edwards ET; Wise GJ Cancer Res; 1994 Dec; 54(24):6306-10. PubMed ID: 7527294 [TBL] [Abstract][Full Text] [Related]
3. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Loric S; Dumas F; Eschwege P; Blanchet P; Benoit G; Jardin A; Lacour B Clin Chem; 1995 Dec; 41(12 Pt 1):1698-704. PubMed ID: 7497608 [TBL] [Abstract][Full Text] [Related]
4. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. Gomella LG; Raj GV; Moreno JG J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297 [TBL] [Abstract][Full Text] [Related]
5. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252 [TBL] [Abstract][Full Text] [Related]
6. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840 [TBL] [Abstract][Full Text] [Related]
7. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619 [TBL] [Abstract][Full Text] [Related]
8. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. Sokoloff MH; Tso CL; Kaboo R; Nelson S; Ko J; Dorey F; Figlin RA; Pang S; deKernion J; Belldegrun A J Urol; 1996 Nov; 156(5):1560-6. PubMed ID: 8863538 [TBL] [Abstract][Full Text] [Related]
9. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications. Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985 [TBL] [Abstract][Full Text] [Related]
11. Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system. Gelmini S; Tricarico C; Vona G; Livi L; Melina AD; Serni S; Cellai E; Magrini S; Villari D; Carini M; Serio M; Forti G; Pazzagli M; Orlando C Clin Chem Lab Med; 2001 May; 39(5):385-91. PubMed ID: 11434386 [TBL] [Abstract][Full Text] [Related]
12. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802 [TBL] [Abstract][Full Text] [Related]
13. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821 [TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction. Noguchi M; Miyajima J; Itoh K; Noda S Int J Urol; 1997 Jul; 4(4):374-9. PubMed ID: 9256327 [TBL] [Abstract][Full Text] [Related]
15. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. Giesing M; Suchy B; Driesel G; Molitor D BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074 [TBL] [Abstract][Full Text] [Related]
17. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248 [TBL] [Abstract][Full Text] [Related]
18. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293 [TBL] [Abstract][Full Text] [Related]
19. Molecular prediction of progression in patients with conservatively managed prostate cancer. McIntyre IG; Clarke RB; Anderson E; Clarke NW; George NJ Urology; 2001 Nov; 58(5):762-6. PubMed ID: 11711356 [TBL] [Abstract][Full Text] [Related]
20. Detection of circulating tumor cells in men with localized prostate cancer. Seiden MV; Kantoff PW; Krithivas K; Propert K; Bryant M; Haltom E; Gaynes L; Kaplan I; Bubley G; DeWolf W J Clin Oncol; 1994 Dec; 12(12):2634-9. PubMed ID: 7527455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]